Michigan
|
1-31773
|
38-2505723
|
||
(State
or other jurisdiction of incorporation)
|
(Commission
file number)
|
(I.R.S.
employer identification no.)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
140.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
d.
|
Exhibits.
|
Exhibit
No.
|
Description
|
3.07
|
Amendment
to Article IV, Section 1 of the Amended and Restated Bylaws of the
Company.
|
3.08
|
Amendment
to Article III, Section 2 of the Amended and Restated Bylaws of the
Company.
|
99.1
|
Press
Release of Caraco Pharmaceutical Laboratories, Ltd., dated October 27,
2009 announcing its results of operations for the second quarter and first
six months of Fiscal 2010.
|
Date: October
27, 2009
|
By: /s/
Jitendra N. Doshi
|
|
Jitendra
N. Doshi
Chief
Executive Officer
|
Amendment
to Article IV, Section 1 of the Amended and Restated Bylaws of the
Company.
|
Amendment
to Article III, Section 2 of the Amended and Restated Bylaws of the
Company.
|
Press
Release of Caraco Pharmaceutical Laboratories, Ltd., dated October 27,
2009 announcing its results of operations for the second quarter and first
six months of Fiscal 2010.
|